The stock of Kura Oncology Inc (KURA) has gone down by -6.13% for the week, with a -1.54% drop in the past month and a -29.17% drop in the past quarter. The volatility ratio for the week is 4.19%, and the volatility levels for the past 30 days are 6.30% for KURA. The simple moving average for the past 20 days is -7.55% for KURA’s stock, with a -52.84% simple moving average for the past 200 days.
Is It Worth Investing in Kura Oncology Inc (NASDAQ: KURA) Right Now?
Moreover, the 36-month beta value for KURA is 0.84. Analysts have varying opinions on the stock, with 11 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for KURA is 72.37M and currently, short sellers hold a 12.78% of that float. On February 28, 2025, KURA’s average trading volume was 1.74M shares.
KURA) stock’s latest price update
Kura Oncology Inc (NASDAQ: KURA) has experienced a decline in its stock price by -1.54 compared to its previous closing price of 7.77. However, the company has seen a fall of -6.13% in its stock price over the last five trading days. seekingalpha.com reported 2025-02-27 that Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Patti Bank – IR Troy Wilson – President and CEO Mollie Leoni – CMO Tom Doyle – SVP of Finance and Accounting Brian Powl – CCO Conference Call Participants Li Watsek – Cantor Fitzgerald Yen-Der Li – Leerink Partners Jason Zemansky – Bank of America Peter Lawson – Barclays Dara Azar – Stifel Charles Zhu – LifeSci Capital David Dai – UBS Justin Zelin – BTIG George Farmer – Scotiabank Operator Good day, everyone, and welcome to today’s Q4 2024 Kura Oncology, Inc. Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Analysts’ Opinion of KURA
UBS, on the other hand, stated in their research note that they expect to see KURA reach a price target of $27. The rating they have provided for KURA stocks is “Buy” according to the report published on October 24th, 2024.
Stifel gave a rating of “Hold” to KURA, setting the target price at $19 in the report published on October 14th of the previous year.
KURA Trading at -7.78% from the 50-Day Moving Average
After a stumble in the market that brought KURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.35% of loss for the given period.
Volatility was left at 6.30%, however, over the last 30 days, the volatility rate increased by 4.19%, as shares sank -0.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.05% lower at present.
During the last 5 trading sessions, KURA fell by -6.13%, which changed the moving average for the period of 200-days by -63.17% in comparison to the 20-day moving average, which settled at $8.27. In addition, Kura Oncology Inc saw -12.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KURA starting from DOYLE THOMAS JAMES, who sale 4,949 shares at the price of $7.87 back on Jan 28 ’25. After this action, DOYLE THOMAS JAMES now owns 88,193 shares of Kura Oncology Inc, valued at $38,958 using the latest closing price.
Leoni Mollie, the Chief Medical Officer of Kura Oncology Inc, sale 4,963 shares at $7.87 during a trade that took place back on Jan 28 ’25, which means that Leoni Mollie is holding 88,253 shares at $39,068 based on the most recent closing price.
Stock Fundamentals for KURA
Current profitability levels for the company are sitting at:
- -171.26 for the present operating margin
- 0.49 for the gross margin
The net margin for Kura Oncology Inc stands at -155.55. The total capital return value is set at -0.5. Equity return is now at value -42.91, with -28.78 for asset returns.
Based on Kura Oncology Inc (KURA), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -10.17. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -135.09.
Currently, EBITDA for the company is -164.96 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 442.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.47.
Conclusion
To wrap up, the performance of Kura Oncology Inc (KURA) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
